Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low-molecular-weight heparin

H Wolf1

  • 1Medical Department, Sandoz AG, Nürnberg, Germany.

The Medical Clinics of North America
|May 1, 1994
PubMed
Summary
This summary is machine-generated.

Low molecular weight heparins (LMWHs) are effective and safe for preventing and treating deep vein thrombosis (DVT). Due to manufacturing differences, LMWH products are not interchangeable but offer improved bioavailability and longer half-lives.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Oral hairy leukoplakia in human immunodeficiency virus positive patients: clinical and etiopathogenic aspects].

Acta otorrinolaringologica espanola·1992
Same author

Reactivities of HIV-1 gag-derived peptides with antibodies of HIV-1-infected and uninfected humans.

AIDS research and human retroviruses·1992
Same author

Assessment of major histocompatibility complex class I interaction with Epstein-Barr virus and human immunodeficiency virus peptides by elevation of membrane H-2 and HLA in peptide loading-deficient cells.

European journal of immunology·1992
Same author

Localization and identification of T-(Gal beta 1-3GalNAc alpha 1-O-R) and T-like antigens in experimental rat bladder cancer.

The Journal of urology·1992
Same author

Human urinary bladder carcinoma glycoconjugates expressing T-(Gal beta(1-3)GalNAc alpha 1-O-R) and T-like antigens: a comparative study using peanut agglutinin and poly- and monoclonal antibodies.

Cancer research·1992
Same author

Determination of placental ferritin (PLF)-positive lymphocytes in women in early stages of breast cancer.

International journal of cancer·1992
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Area of Science:

  • Pharmacology
  • Thrombosis Research
  • Drug Development

Background:

  • Low molecular weight heparins (LMWHs) are defined by their molecular weight range (3000-10,000 daltons).
  • Manufacturing processes vary significantly between LMWH products, rendering them non-comparable and unique.
  • Common characteristics include enhanced bioavailability via subcutaneous administration and prolonged biological half-life.

Purpose of the Study:

  • To review the efficacy and safety of LMWHs.
  • To highlight their established role in deep vein thrombosis (DVT) prophylaxis and treatment.
  • To underscore the distinct nature of individual LMWH products.

Main Methods:

  • Review of numerous clinical trials and available scientific literature.
  • Analysis of pharmacokinetic and pharmacodynamic properties of LMWHs.

Related Experiment Videos

  • Evaluation of approved indications and clinical applications.

    • Main Results:

    • LMWHs demonstrate high efficacy and safety in postsurgical deep vein thrombosis (DVT) prophylaxis.
    • Evidence supports LMWH use for DVT prophylaxis in medical conditions.
    • LMWHs are also effective in treating established DVT.

    Conclusions:

    • LMWHs are a cornerstone in DVT prevention and treatment.
    • The unique properties of each LMWH necessitate individualized product selection.
    • Further research may explore specific clinical advantages of different LMWH formulations.